For the millions of sufferers of dry eye syndrome, their only recourse to easing the painful condition is to use drug-laced eye drops three times a day. Now, researchers from the University of Waterloo have developed a topical solution containing nanoparticles that will combat dry eye syndrome with only one application a week.
The eye drops progressively deliver the right amount of drug-infused nanoparticles to the surface of the eyeball over a period of five days before the body absorbs them. One weekly dose replaces 15 or more to treat the pain and irritation of dry eyes.
The nanoparticles, about 1/1000th the width of a human hair, stick harmlessly to the eye’s surface and use only five per cent of the drug normally required.
“You can’t tell the difference between these nanoparticle eye drops and water,” said Shengyan (Sandy) Liu, a PhD candidate at Waterloo’s Faculty of Engineering, who led the team of researchers from the Department of Chemical Engineering and the Centre for Contact Lens Research. “There’s no irritation to the eye.”
Dry eye syndrome is a more common ailment for people over the age of 50 and may eventually lead to eye damage. More than six per cent of people in the U.S. have it. Currently, patients must frequently apply the medicine three times a day because of the eye’s ability to self-cleanse—a process that washes away 95 per cent of the drug.
“I knew that if we focused on infusing biocompatible nanoparticles with Cyclosporine A, the drug in the eye drops, and make them stick to the eyeball without irritation for longer periods of time, it would also save patients time and reduce the possibility of toxic exposure due to excessive use of eye drops,” said Liu.
The research team is now focusing on preparing the nanoparticle eye drops for clinical trials with the hope that this nanoparticle therapy could reach the shelves of drugstores within five years.
For the millions of sufferers of dry eye syndrome, their only recourse to easing the painful condition is to use drug-laced eye drops three times a day. Now, researchers from the University of Waterloo have developed a topical solution containing nanoparticles that will combat dry eye syndrome with only one application a week.
The eye drops progressively deliver the right amount of drug-infused nanoparticles to the surface of the eyeball over a period of five days before the body absorbs them. One weekly dose replaces 15 or more to treat the pain and irritation of dry eyes.
The Latest on: Drug-infused nanoparticle
[google_news title=”” keyword=”Drug-infused nanoparticle” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Drug-infused nanoparticle
- Nanoparticle-Based Therapy Shows Promise in Eradicating Tumorson March 28, 2024 at 7:35 am
A nanoparticle-based therapy developed by UT Southwestern Medical Center scientists stimulated an immune pathway that eradicated tumors in mouse models of various cancer types.
- Biocompatible nanoparticles modified with ATP can enhance systemic delivery of cancer immunotherapyon March 27, 2024 at 9:47 am
Purdue University researchers are developing and validating patent-pending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, to enhance immunotherapy ...
- Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapyon March 27, 2024 at 7:19 am
WEST LAFAYETTE, Ind. — Purdue University researchers are developing and validating patent-pending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, ...
- Intellia ending work with Regeneron on gene therapy for hemophilia Bon March 27, 2024 at 5:02 am
Intellia is leaving an agreement with Regeneron that had the two co-developing a hemophilia B gene therapy using CRISPR/Cas9 technology.
- Promising Outlook: Metal & Metal Oxide Nanoparticles Market to Surpass US$ 89,894.6 Million by 2032on March 26, 2024 at 8:53 pm
According to research conducted by Future Market Insights on the metal and metal oxide nanoparticles market, demand is estimated to reach a valuation of US$ 89,894.6 million by the end of the ...
- Researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapyon March 23, 2024 at 5:00 pm
Researchers are enhancing immunotherapy effects against malignant tumors by developing and validating patent-ending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine ...
- Antimicrobial Wipes Market: Expected Advancement at a 10% CAGR by 2033on March 19, 2024 at 12:09 am
In 2023, the antimicrobial wipes market is estimated to be valued at US$ 10.04 billion and is expected to reach US$ 27 billion by 2033. The adoption of antimicrobial wipes is likely to advance at a ...
via Bing News